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Relationship Between b-cell Response and Insulin Sensitivity in
Horses based on the Oral Sugar Test and the Euglycemic
Hyperinsulinemic Clamp
S. Lindase , K. Nostell, J. S€oder, and J. Br€ojer
Background: A hyperbolic relationship between b-cell response and insulin sensitivity (IS) has been described in several
species including rodents, dogs, and humans. This relationship has not been elucidated in the horse.
Hypothesis/Objectives: To determine whether the hyperbolic relationship between b-cell response and IS exists in horses
by using indices of b-cell response from the oral sugar test (OST) and IS measurements from the euglycemic hyperinsulinemic
clamp (EHC). A second aim was to compare how well IS estimates from the OST and EHC correlate.
Animals: Forty-nine horses with diﬀerent degrees of insulin regulation (normal-to-severe insulin dysregulation).
Methods: Cross-sectional study. Horses were examined with an OST and an EHC.
Results: Decreased IS was associated with increased b-cell response in the horses. Nine of 12 comparisons between indices
of b-cell response and IS measures fulﬁlled the criteria for a hyperbolic relationship. Indices of IS calculated from the OST
correlated highly with the insulin-dependent glucose disposal rate (M) and the insulin-dependent glucose disposal rate per
unit of insulin (M/I) determined from the EHC (r = 0.81–0.87).
Conclusions and Clinical Importance: A hyperbolic relationship between b-cell response and IS exists in horses, which sug-
gest that horses with insulin dysregulation respond not only with postprandial hyperinsulinemia but are also insulin resistant.
The OST is primarily a test for b-cell response rather than a test for IS, but calculated indices of IS from the OST may be
useful to estimate IS in horses, especially when the horse is insulin resistant.
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Insulin dysregulation (ID), a key feature of the equinemetabolic syndrome (EMS), is a nonspeciﬁc term
used to describe horses with abnormalities in their insu-
lin metabolism encompassing either fasting hyperinsu-
linemia, excessive insulin response to sugars, or insulin
resistance (IR).1 The euglycemic hyperinsulinemic clamp
(EHC) is considered to be the gold standard for mea-
surements of tissue IR, but the test is costly, complex,
and time-consuming.2,3 The recently developed oral
sugar test (OST),4 a modiﬁed variant of the oral glu-
cose tolerance test (OGTT),5 is easier to perform and
generates information about both glucose disposal and
insulin secretion from the b-cells in the pancreas.3,6
Theoretically, the oral tolerance tests (OST and OGTT)
are therefore suitable for estimating both insulin
sensitivity (IS) and b-cell response.6 The oral tolerance
tests generally are considered to be less speciﬁc for
measuring b-cell response compared to the hyper-
glycemic clamp, because the insulin secretion pattern
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AUCINS/GLU-30 incremental area under the curve for insulin/glucose
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CNS cresty neck score
CV coeﬃcient of variation
DI disposition index
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ISI60 60-minutes insulin sensitivity index
ISI90 90-minutes insulin sensitivity index
ISICOMP composite whole-body insulin sensitivity index
ISIPEAK peak insulin sensitivity index
M mean insulin-dependent glucose disposal rate
M/I mean insulin-dependent glucose disposal rate per unit
of insulin
NIMGU non-insulin-mediated glucose uptake
NIR normal insulin regulation
OST oral sugar test
PeakINS peak insulin concentration during OST
SD standard deviation
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after oral glucose administration reﬂects the combined
response to several physiological factors such as gastric
emptying, degree of hepatic glucose trapping, and incre-
tin eﬀects. Still, administration of sugars PO more clo-
sely mimics a physiological stimulation of insulin
secretion compared to the IV tests.3,6,7 The oral toler-
ance tests also have been used to calculate indices of IS
(eg, composite whole-body insulin sensitivity index
[ISICOMP]) in both humans and horses.
8,9 These indices
are not speciﬁc quantiﬁcations of IS but have been
shown to correlate well with IS measured by the EHC
in humans.8,10
The b-cell response and IS are dependent on each
other, whereby changes in 1 feature are mirrored by a
reciprocal adaptation in the other.11 A nonlinear inverse
relationship between b-cell response and IS was ﬁrst
described in humans in 1981,12 and this relationship
was further characterized and described in 1993 as rect-
angular hyperbolic.13 The hyperbolic relationship
between b-cell response and IS has, during the last few
decades, been described in several species including
rodents, dogs, and humans13–15 but has, to the authors’
knowledge, not been elucidated in horses. In a rectan-
gular hyperbolic relationship, the product of b-cell
response and IS is constant for a given degree of glu-
cose tolerance. This product is called disposition index
(DI) and represents an index of b-cell function related
to the patient’s IS. A decrease in DI is thus an indica-
tion of altered b-cell function, resulting in inability to
compensate for decreased IS (ie, impaired glucose toler-
ance and type 2 diabetes mellitus).16
The aim of our study was to test whether a rectangu-
lar hyperbolic relationship exists between b-cell response
and IS, by comparing OST-derived indices of b-cell
response with IS measured by the EHC, in horses with
variable degrees of insulin regulation (normal-to-severe
ID). One further aim was to compare how well indices
of IS derived from the OST correlate with quantitative
measurements of IS determined by the gold standard
EHC.
Materials and Methods
Horses
The study was approved by the Ethical Committee for Animal
Experiments, Uppsala, Sweden. Forty-nine horses with diﬀerent
degrees of insulin regulation (normal-to-severe ID) were used in
the study. The horses were owned by the Swedish University of
Agricultural Sciences, the National Council Horse Facility, or pri-
vately owned. Criteria for inclusion were as follows: normal ﬁnd-
ings on clinical examination except for general obesity, regional
obesity, or both, age ≥4 years, negative test results for pituitary
pars intermedia dysfunction (normal plasma ACTH concentration)
at the start of the study as well as no ongoing episode of laminitis.
The privately owned horses were recruited from a group of horses
previously diagnosed with ID and referred to the University Ani-
mal Hospital, Swedish University of Agricultural Sciences for an
extended examination. The horses owned by the Swedish Univer-
sity of Agricultural Sciences or by the National Council Horse
Facility were examined in their home environment. All horses in
the study were fed a hay or haylage diet supplemented with miner-
als. Horses were housed in individual box stalls and allowed daily
turnout in a dirt or sand paddock. None of the horses had been
on grass pasture for at least 2 months before testing.
Experimental Design
All horses were acclimatized for at least 48 hours to the envi-
ronment where sampling was to take place. After acclimatization,
horses were screened with an OST followed by an EHC the next
day. Both the OST and the EHC commenced after 12 hours of
feed withdrawal overnight, but with free access to water. Based on
results from the OST performed as part of the study, horses were
allocated into 2 diﬀerent groups: normal insulin regulation (NIR;
peak insulin concentration <45 lIU/mL) and ID (peak insulin dys-
regulation ID>45 lIU/mL).a
OST—Oral Sugar Test
The day before testing an IV catheterb was inserted asepti-
cally into 1 of the jugular veins under local anesthesia.c The
OST procedure was conducted as described previously.17 Brieﬂy,
Dan Sukker Glykossirapd was syringed PO at a dosage of
0.2 mL/kg body weight. Blood samples were collected from the
jugular catheter into evacuated tubese containing lithium hep-
arin, immediately before (5 minutes), and at 30, 60, 90, 120,
150, and 180 minutes after the PO administration of syrup.
Tubes were placed on ice immediately after sampling and cen-
trifuged within 5 minutes for 10 minutes at 2,700 9 g. Plasma
was subsequently harvested, frozen rapidly, and stored at 80°C
until later analysis of plasma glucose and plasma insulin concen-
trations (see below).
Plasma glucose and plasma insulin concentrations from the
OST were used to calculate 6 indices of b-cell response: peak insu-
lin concentration (PeakINS), insulinogenic index (INSINDEX),
18,19
incremental area under the insulin curve for the time interval 0–
180 minutes (AUCINS-180),
20,21 and the ratio of the incremental
area under the insulin curve to the incremental area under the glu-
cose curve for the time intervals 0–30, 0–120, and 0–180 minutes
(AUCINS/GLU-30, AUCINS/GLU-120 and AUCINS/GLU-180).
22 The
glucose and insulin data from the OST also were used for calcula-
tion of an IS index: ISICOMP.
8 In addition, new simpliﬁed methods
to calculate ISICOMP using fewer time points were introduced:
peak insulin sensitivity index (ISIPEAK), 60-minutes insulin sensi-
tivity index (ISI60), and 90-minutes insulin sensitivity index (ISI90).
The INSINDEX was calculated as (I30I0)/(G30G0), where
I30 = insulin concentration at 30 minutes of OST, I0 = baseline
insulin concentration, G30 = glucose concentration at 30 minutes
of OST, and G0 = baseline glucose concentration.
The AUCINS-180, AUCINS/GLU-30, AUCINS/GLU-120, and
AUCINS/GLU-180 were calculated by use of the trapezoid method.
f
The ISICOMP was calculated using the following formula:
1,000/
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðGIÞðMGMIÞp , where G = baseline glucose concentra-
tion, I = baseline insulin concentration, MG = mean glucose con-
centration during the OST, and MI = mean insulin concentration
during the OST.
The ISIPEAK, ISI60, and ISI90 were calculated as:
100/
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðGpeakIpeak
p Þ, 100/ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðG60I60Þp , and 100/ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðG90I90Þp respec-
tively, where Gpeak = peak glucose concentration, Ipeak = peak
insulin concentration, G60 = glucose concentration at 60 minutes,
I60 = insulin concentration at 60 minutes, G90 = glucose concen-
tration at 90 minutes, I90 = insulin concentration at 90 minutes
during the OST.
EHC—Euglycemic Hyperinsulinemic Clamp
After the OST examination, a second IV catheterb was
inserted into the contralateral jugular vein. On the morning of
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the following day, blood samples for determination of baseline
concentrations of plasma glucose and plasma insulin were drawn
from 1 of the IV catheters immediately before (10, 5, and
1 minute) the start of the EHC. The EHC procedure has previ-
ously been described for use in horses.23,24 Brieﬂy, a continuous
rate infusion of glucoseg and recombinant human insulinh was
initiated through 1 of the jugular catheters, with a multichannel
volumetric infusion pump.i The infusion rate for insulin was held
constant at 3 mIU/kg/min, and a variable rate of glucose was
infused to maintain blood glucose concentration at euglycemia
(5 mmol/L) during the 3-hour infusion. The glucose infusion rate
was adjusted if the concentration deviated by more than
0.2 mmol/L from euglycemia. Blood samples were obtained every
5 minutes for immediate analysis of blood glucose concentration
with a handheld glucometerj and every 10 minutes throughout
the EHC for subsequent determination of plasma glucose (10-
minutes intervals) and plasma insulin (20-minutes intervals) con-
centrations. These blood samples were collected into evacuated
tubese containing lithium heparin and placed on ice for 5 min-
utes before centrifugation (10 minutes, 2,700 9 g). Plasma was
separated, frozen rapidly, and stored at 80°C until later analy-
sis of plasma glucose and plasma insulin concentrations (see
below).
The ﬁrst 120 minutes of the EHC was considered an equilibra-
tion period. Plasma glucose and plasma insulin concentrations
from the ﬁnal 60 minutes (steady state) were used for calculation
of the total mean glucose disposal rate (M60) and the mean insulin
concentration (I).23 The non-insulin-mediated glucose uptake
(NIMGU) at euglycemia (5 mmol/L) was estimated to be 0.57 mg/
kg/min. This value was obtained by extrapolating data from
NIMGU during hyperglycemic clamps in horses25 using the strong
linear relationship that has been demonstrated between plasma
glucose concentration and NIMGU during stepwise hyperglycemic
clamps.26 The intercept was set to 0. The mean insulin-dependent
glucose disposal rate (M) then was calculated as M60 – NIMGU
and expressed per unit of insulin (M/I).
Analysis of Blood Samples
Plasma glucose concentrations were measured enzymatically
with an automated clinical chemistry analyzer.k Endogenous
equine plasma insulin concentrations from the OST were deter-
mined using a commercial equine-optimized ELISAl evaluated for
use in horses,27 and insulin concentrations were controlled for with
a commercial kit.m Plasma insulin concentrations from the contin-
uous rate infusion of recombinant human insulin during the EHC
procedures were determined using a commercial ELISAn designed
for use in humans, and a commercial kito was used as a control.
All analyses of plasma glucose and plasma insulin concentrations
were performed in duplicate. The mean intra-assay coeﬃcients of
variation (CVs) calculated from samples run in duplicate for glu-
cose, equine insulin (equine-optimized ELISA), and human insulin
(human ELISA) were 0.6, 2.2, and 2.7%, respectively. The equine-
optimized ELISAl previously has been evaluated in our laboratory
with reported intra-assay CVs between 2.0 and 6.5% and an
interassay CV of 10.7%.27
Statistical Analysis
All data were analyzed using JMP Pro 11.2.0.p
Diﬀerences in physical characteristics (age, body condition
score [BCS], cresty neck score [CNS], and body weight), EHC
data (M and M/I), and time to PeakINS during OST were com-
pared between the NIR and ID groups by use of an independent
t-test or a nonparametric test (Wilcoxon rank-sum test) as
appropriate.
The rectangular hyperbolic function (y = constant 9 1/x), can
be re-expressed as a linear model by log-transformation of data
producing the following equation: Ln (y) = constant + b 9 Ln
(x), where b is the regression coeﬃcient. This linear function was
used to determine the b for the diﬀerent combinations of
OST-derived indices of b-cell response (dependent variable) and
EHC-derived sensitivity measures (independent variable). The 95%
conﬁdence interval (CI) for b was calculated by using the boot-
strap method with 1,000 replications randomly selected from the
original data. A rectangular hyperbolic relationship between b-cell
response and IS was established if b was approximately equal to
1 (a criterion that was fulﬁlled if the 95% CI for b included 1),
and if the 95% CI for b excluded zero. The linear regressions were
run by the ﬁt orthogonal command in the bivariate platform. This
model adjusts for measurement errors in both the y (dependent)
and x (independent) variables. The error estimates for OST-
derived indices of b-cell response were based on repeated testing
performed by our research group with 17 healthy horses, where
mean CVs of 19.4, 26.1, 23.3, 25.9, 24.4, and 28.0% were found
for PeakINS, INSINDEX, AUCINS-180, AUCINS/GLU-30, AUCINS/
GLU-120, and AUCINS/GLU-180, respectively. The error estimates for
EHC-derived sensitivity measures were based on previously
published data reporting mean CVs of 12.2 and 14.1% for M and
M/I, respectively.28
To examine how well IS indices derived from the OST
(ISICOMP, ISIPEAK, ISI60, and ISI90) correlated with EHC-derived
sensitivity measures (M and M/I), linear regression analyses were
performed. Data were logarithmically transformed before analysis,
to correct for skewed distribution of residuals.
Values of P < 0.05 were considered as signiﬁcant for all analy-
ses. All data are presented as mean  standard deviation (SD)
except for non-normally distributed data, which are presented as
median and interquartile range.
Results
Horses
All horses fulﬁlled the inclusion criteria for the study.
Based on results from the OST, 23 and 26 horses,
respectively, were allocated into the NIR and the ID
groups. None of the horses included in the NIR group,
but 62% (16/26) of horses, included in ID group, had a
previous history of laminitis. Physical characteristics for
horses included in the study are reported in Table 1.
Horses in the ID group had higher BCS (P < 0.0001)
and CNS (P < 0.0001) than horses in the NIR group.
Table 1. Physical characteristics for horses (n = 49)
included in the study divided into normal insulin regula-
tion (NIR) and insulin dysregulation (ID) groups.
NIR
n = 23
ID
n = 26
Sex (g/m) 12/11 5/21
Age (y) 9.5  3.9a 14.1  4.3b
Body weight 424  101a 423  116a
BCS (1–9) 5.3  0.6a 6.7  1.1b
CNS (0–5) 2.2  0.5a 3.5  0.7b
SD, standard deviation; g, gelding; m, mare; BCS, body condi-
tion score; CNS, cresty neck score.
Data are mean  SD. a,bMeans with diﬀerent superscript letters
diﬀer signiﬁcantly within row (P < 0.05).
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The breeds represented in the NIR group were Stan-
dardbred (n = 10), Icelandic horse (n = 6), Swedish
warmblood (n = 1), and Gotland pony (n = 6). The ID
group included the following breeds: Fjord horse
(n = 2), Icelandic horse (n = 10), Shetland pony (n = 2),
Welsh cob (n = 1), Highland pony (n = 1), Swedish
warmblood (n = 2), Standardbred (n = 4), Swedish rid-
ing pony (n = 1), crossbreed horse or pony (n = 2), and
Hanoverian (n = 1).
Oral Sugar Test and Euglycemic Hyperinsulinemic
Clamp
The median PeakINS for horses in the NIR and ID
groups were 28 (20–36) lIU/mL and 149 (89–
223) lIU/mL, respectively. There was no diﬀerence in
median time to PeakINS (P = 0.01) between the NIR
(90 (30–90) minutes) and ID (90 (60–120) minutes)
groups. For 3 of the horses, the early glucose
response, insulin response, or both were delayed.
Indices for early b-cell response (INSINDEX and
AUCINS/GLU-30) could therefore not be obtained for
these horses.
The plasma glucose concentration during the ﬁnal
60 minutes (steady state) of the EHC had a mean CV
of 3.8  1.6. Horses in the NIR group had higher M
(P < 0.0001) and M/I (P < 0.0001) compared to horses
in the ID group. The median values for M and M/I
were 2.8 (2.2–3.6) mg/kg/min and 5.2 (4.1–6.8) (mg/kg/
min 9 103)/(lIU/mL) for the NIR group and 0.8 (0.5–
1.1) mg/kg/min and 0.9 (0.6–2.0) (mg/kg/min 9 103)/
(lIU/mL) for the ID group.
Hyperbolic Relationship Between b-cell Response and
Insulin Sensitivity
The estimated regression coeﬃcient (b), correlation
coeﬃcient (r), and the 95% CI for b obtained from
regression analysis comparing OST-derived indices of b-
cell response and EHC-derived sensitivity measures are
shown in Table 2. Scatter plots with data for 6 indices
of b-cell response (PeakINS, AUCINS-180, INSINDEX,
AUCINS/GLU-30, AUCINS/GLU-120, or AUCINS/GLU-180)
versus 2 measurements of IS (M or M/I) illustrate a
nonlinear inverse relationship (Figs 1 and 2). A rectan-
gular hyperbolic relationship was evident in 9 of the 12
aforementioned comparisons using the following model:
Ln (y) = constant + b 9 Ln (x). As IS decreased, the
b-cell response increased.
Correlation Between OST-Derived IS Indices and
Sensitivity Measures from the EHC
Selected scatter plots showing the correlation between
OST-derived IS indices (ISIPEAK and ISICOMP) and the
M/I are presented on the original scale and after log-
transformation (Fig 3). Data on the original scale
showed heteroscedasticity. All IS indices derived from
the OST were highly correlated with M and M/I
derived from the EHC (r = 0.81–0.87; P < 0.0001;
Table 3).
Discussion
We found a nonlinear inverse relationship for all 12
comparisons between indices of b-cell response obtained
from the OST and the quantitative IS measurements
obtained by the EHC. A rectangular hyperbolic rela-
tionship was evident in 9 of these 12 comparisons,
which justiﬁes the use of DI as a measure of pancreas
functionality under these 9 speciﬁc conditions. The
results of the study conﬁrm that a reciprocal relation-
ship between b-cell response and IS exists in horses and
that the OST primarily is a test for b-cell response
rather than a test for IS. Despite these ﬁndings, calcu-
lated indices of IS from the OST may be useful to esti-
mate IS in horses, especially when the horse is in a state
of IR.
It is well known that IR is associated with increased
insulin secretion from the b-cells.11–14 Insulin sensitivity
and b-cell response have been shown to be inversely
related in order to maintain glucose tolerance in
humans and dogs.13,14,16 Our results support that a sim-
ilar relationship exists in horses. Because of the nature
of this nonlinear inverse relationship between the b-cell
response and the IS, the magnitude in the b-cell
response that follows a change in IS will depend on the
horse’s initial degree of IS. This means that horses with
Table 2. Correlation coeﬃcient (r), regression coeﬃ-
cient (b), and 95% conﬁdence interval for b for combi-
nations of oral sugar test derived indices of b-cell
response and euglycemic hyperinsulinemic clamp
derived sensitivity measures used in the regression
model: Ln (y) = constant + b 9 Ln (x). Three of the 49
horses had a delayed early glucose and/or insulin
responses during OST, resulting in missing data for
INSINDEX and AUCINS/GLU-30.
b-cell response
Sensitivity
measures r
b
(95% CI)
PeakINS M 0.84 1.30 (1.50 to 1.10)
PeakINS M/I 0.84 1.03* (1.22 to 0.90)
INSINDEX M 0.77 1.03* (1.32 to 0.92)
INSINDEX M/I 0.87 1.10* (1.30 to 0.99)
AUCINS-180 M 0.87 1.40 (1.62 to 1.19)
AUCINS-180 M/I 0.86 1.12* (1.35 to 0.96)
AUCINS/GLU-30 M 0.77 1.04* (1.33 to 0.80)
AUCINS/GLU-30 M/I 0.73 0.80* (1.01 to 0.59)
AUCINS/GLU-120 M 0.81 1.17* (1.44 to 1.00)
AUCINS/GLU-120 M/I 0.80 0.92* (1.19 to 0.83)
AUCINS/GLU-180 M 0.81 1.16 (1.43 to 1.02)
AUCINS/GLU-180 M/I 0.80 0.91* (1.17 to 0.82)
PeakINS, peak insulin concentration during OST; INSINDEX,
insulinogenic index; AUCINS-180, incremental area under the curve
for insulin at 180 min of OST; AUCINS/GLU-30, incremental area
under the curve for insulin/glucose at 30 min of OST; AUCINS/
GLU-120, incremental area under the curve for insulin/glucose at
120 min of OST; AUCINS/GLU-180, incremental area under the
curve for insulin/glucose at 180 min of OST; M, mean insulin-
dependent glucose disposal rate; M/I, mean insulin-dependent glu-
cose disposal rate per unit of insulin.
*Indicate rectangular hyperbolic relationship within row
(P < 0.05).
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Fig 1. Scatter plots of individual horse data (n = 49) showing the relationship between oral sugar test derived indices of b-cell response:
PeakINS (A), AUCINS-180 (B), INSINDEX (C), AUCINS/GLU-30 (D), AUCINS/GLU-120 (E), and AUCINS/GLU-180 (F) versus the mean insulin-
dependent glucose disposal rate (M), in horses with normal insulin regulation (NIR, black circle) and insulin dysregulation (ID with previ-
ous history of laminitis, orange downward pointing triangle; ID without previous history of laminitis, blue upward pointing triangle). A
solid line (line of best ﬁt) represents a rectangular hyperbolic curve ﬁtted to the data. The curve is based on the function
(y = constant 9 1/x), where the constant = disposition index. Data that fulﬁll the statistical criteria of a rectangular hyperbolic curve have
the equation in the ﬁgure (C, D and E). Three of the horses had a delayed early glucose and/or insulin responses during OST, resulting in
missing data for INSINDEX and AUCINS/GLU-30.
Fig 2. Scatter plots of individual horse data (n = 49) showing the relationship between oral sugar test derived indices of b-cell response:
PeakINS (A), AUCINS-180 (B), INSINDEX (C), AUCINS/GLU-30 (D), AUCINS/GLU-120 (E), and AUCINS/GLU-180 (F) versus the mean insulin-
dependent glucose disposal rate per unit of insulin (M/I), in horses with normal insulin regulation (NIR, black circle) and insulin dysregu-
lation (ID with previous history of laminitis, orange downward pointing triangle; ID without previous history of laminitis, blue upward
pointing triangle). A solid line (line of best ﬁt) represents a rectangular hyperbolic curve ﬁtted to the data. The curve is based on the func-
tion (y = constant 9 1/x), where the constant = disposition index. Data that fulﬁll the statistical criteria of a rectangular hyperbolic curve
have the equation in the ﬁgure (A - F). Three of the horses had a delayed early glucose and/or insulin responses during OST, resulting in
missing data for INSINDEX and AUCINS/GLU-30.
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high IS will have small increases in their b-cell response
following large decreases in IS, whereas horses with
markedly decreased IS will have large changes in their
b-cell response associated with small changes in IS. As
a result, diagnostic tests that are designed to measure
the b-cell response (eg, OST) are dependent on the
patient’s degree of IS. In addition, the results of the
OST also are aﬀected by several physiological factors
such as gastric emptying and hepatic glucose
trapping,3,7 contributing to the relatively high variability
among the indices of b-cell response found in previous
studies.4,17 Thus, calculated indices for b-cell response
derived from the OST appear to have a lower ability to
estimate changes in IS as long as the patient is within
the normal sensitivity range. These inherent characteris-
tics of the OST suggest that the test may not be the
most ideal diagnostic method for identiﬁcation of
horses with very mild IR or horses close to developing
IR, despite being a test more closely aligned with physi-
ologic situations in which horses have been shown to
have had an increased risk for developing laminitis (eg,
grazing situations). However, when the degree of IS
decrease is more pronounced (ie, IR), the function of
the b-cells becomes upregulated, which makes the test
very useful to diagnose IR and to monitor improve-
ments or deteriorations in IS. Several studies have
linked laminitis to excessive hyperinsulinemia29,30 or to
markedly increased serum insulin concentrations in IR
horses on pasture.31 Although we do not have conclu-
sive evidence in our results, it is interesting that 14 of
the 18 horses that had PeakINS >100 lIU/mL or
M-value <1.0 mg/kg/min, suggesting more advanced
IR, had a previous history of laminitis. Thus, it appears
that laminitis is more strongly associated with advanced
IR or pronounced postprandial hyperinsulinemia rather
than very mild IR, which suggests that the OST is a
suitable and sensitive test for identifying horses at risk
for developing laminitis secondary to ID. In a recent
study, the OST was found to be highly speciﬁc but had
a poor sensitivity for diagnosing IR.32 One problem
with the majority of the diagnostic tests for ID is the
lack of comparison to a gold standard and the use of
arbitrary cutoﬀ values. A recent study33 comparing
results of OST to a gold standard showed that a much
lower cutoﬀ concentration for insulin (30.2 mIU/mL) is
indicative of IR compared to the previously suggested
Fig 3. Scatter plots showing the relationship between the oral sugar test derived insulin sensitivity indices: ISIPEAK (A, B) and ISICOMP
(C, D) and the mean insulin-dependent glucose disposal rate per unit of insulin (M/I) calculated from the euglycemic hyperinsulinemic
clamp, on the original scale (A, C) and after log-transformation (B, D), in horses with normal insulin regulation (NIR, black circle) and
insulin dysregulation (ID with previous history of laminitis, orange downward pointing triangle; ID without previous history of laminitis,
blue upward pointing triangle). The solid line is the regression line (line of best ﬁt), and the dashed lines are 95% CI of the best ﬁt (CI for
the mean response).
Table 3. Linear regression analysis for oral sugar test
derived insulin sensitivity indices (ISICOMP, ISIPEAK,
ISI60, and ISI90) and euglycemic hyperinsulinemic clamp
derived sensitivity measures (M and M/I).
IS indices
Ln M Ln M/I
r P-value r P-value
LnISICOMP 0.85 < 0.0001 0.86 < 0.0001
LnISIPEAK 0.83 < 0.0001 0.83 < 0.0001
LnISI60 0.83 < 0.0001 0.82 < 0.0001
LnISI90 0.81 < 0.0001 0.82 < 0.0001
Ln, the natural logarithm; r, correlation coeﬃcient; ISICOMP,
composite whole-body insulin sensitivity index; ISIPEAK, peak
insulin sensitivity index; ISI60, 60-min insulin sensitivity index and
ISI90, 90-min insulin sensitivity index; M, mean insulin-dependent
glucose disposal rate; M/I, mean insulin-dependent glucose dis-
posal rate per unit of insulin.
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arbitrary cutoﬀ concentration (60 mIU/mL). The cutoﬀ
concentration for the OST used in our study is also
lower (45 mIU/mL)a. This cutoﬀ concentration for the
diagnosis of IR is based on speciﬁc analyses comparing
OST results to quantitative measurements of IS using a
receiver operating characteristic curve.
In a rectangular hyperbolic relationship, the product
of b-cell response and IS is constant for a given degree
of glucose tolerance. This product, DI,12,13,16 can be
considered a measure of pancreas functionality (ie, a
measure of the b-cells’ ability to compensate for
decreased IS). During development of IR, the b-cells’
release of insulin is increased and compensation will be
adequate as long as DI remains constant (ie, normal
glucose tolerance).13,16 When the b-cells’ release of insu-
lin becomes inadequate in relation to IR, glucose intol-
erance and type 2 diabetes mellitus develop, which is
associated with a decrease in DI. The decrease in DI is
represented by deviation of the hyperbolic curve closer
toward the origin (Fig 4).34,35 In horses, type 2 diabetes
mellitus is rare, and the b-cells appear to fully compen-
sate for the IR over a long time period. Postprandial
hyperinsulinemia after feeding or grazing in horses with
IR is a risk factor for developing laminitis.36–39 The
most accepted theory is that abnormal hyperinsulinemia
post-feeding is related to the degree of decreased IS, as
part of the b-cells’ compensatory response.40–42 An
alternative explanation is that hyperinsulinemia is the
primary cause and IR the compensatory or adaptive
response.43–45 It has recently been suggested that abnor-
mal hyperinsulinemia during the postprandial phase
may occur in horses without the presence of decreased
IS.1 In contrast, the data from our study showed that
postprandial hyperinsulinemia in response to oral glu-
cose is highly related to the patient’s degree of IS. Pro-
nounced hyperinsulinemia after an oral glucose load in
horses with normal IS without a compensatory decrease
in IS will cause hypoglycemia (Fig 4). Instead, abnor-
mal hyperinsulinemia as a driving force for developing
ID will likely have an adaptive response in IR to pre-
vent its occurrence.43,45 In a recent study, horses with
ID were found to have increased glucose bioavailability
along with increased insulin response.46 Horses with a
more exaggerated increase in glucose bioavailability and
secondary hyperinsulinemia could have a delayed adap-
tive response in IR, which could cause an increased DI
and deviation of the hyperbolic curve farer from origin
(Fig 4). The deviation of DI is thus in the opposite
direction compared to patients with type 2 diabetes mel-
litus. Our study is one of very few studies in which the
degree of IS has been quantiﬁed in horses with ID and
it emphasizes the importance of determining the b-cell
response in conjunction with more accurate determina-
tions of the degree of IS (ie, the EHC or the frequently
sampled IV glucose tolerance test with MinMod analy-
sis) to better understand the pathophysiology of ID.
Whether or not a distinct reciprocal association between
the b-cell response and the degree of IS was found, the
results do not allow diﬀerentiation of whether IR is the
cause of ID or the adaptive response to postprandial
hyperinsulinemia.
Several studies in humans have emphasized the
importance of assessing both IS and b-cell response in
the same subject to reach appropriate conclusions about
b-cell function.13,35,47 However, measurements of IS and
b-cell response must be as independent as possible,
which is not the case for all tests. For example, results
for indices of b-cell response obtained from the OST
are intrinsically related to calculated indices of IS from
the same test, because the same glucose and insulin data
are used for both calculations. To avoid this error, we
used 2 independent methods to assess the b-cell
response and the IS, the OST, and the EHC.
In humans, the DI has been calculated from IS mea-
sured by the frequently sampled IV glucose tolerance
test, the EHC and the OGT in conjunction with
measurements of the b-cell response obtained from the
frequently sampled IV glucose tolerance test, hyper-
glycemic clamp, or the OGT.13,22,47–49 These calculated
DI are not identical, and a speciﬁc DI is only valid for
comparison as long as the same test protocols and ana-
lytical methods are used for all patients. Even if there is
a nonlinear inverse relationship between b-cell response
and IS to maintain glucose tolerance at a stable level,
the relationship may not always fulﬁll the mathematical
criteria for a rectangular hyperbolic relationship.50 This
is not surprising because the relationship is dependent
Fig 4. Schematic diagram illustrating the characteristics of the
hyperbolic relationship between b-cell response and insulin sensi-
tivity (IS) and the product of the 2 parameters, the disposition
index (DI). State 1: A horse with normal IS and normal b-cell
response. State 2: The horse compensates for decreased IS by
increasing b-cell responsivity, and the DI is unchanged compared
to state 1 (ie, remains on the same hyperbolic curve). State 3: The
horse fails to compensate for the decreased IS, the b-cell response
remains normal while the DI is decreased (a deviation of the
hyperbolic curve toward origin). State 4: The horse develops an
increased b-cell response with a delayed adaptive decrease in IS (a
deviation of the hyperbolic curve farer from origin; increased DI).
State 5: The horse develops hyperinsulinemia without an adaptive
decrease in IS. The IS is unchanged but the hyperinsulinemia is
increased and follows the direction of the gray arrow. The horse
will develop hypoglycemia when the increased b-cell response
reaches a certain level because there is no adaptive decrease in IS.
In state 2, the glucose tolerance remains normal due to the ade-
quate compensatory increase in b-cell response. State 3 illustrates
a typical response for a horse with impaired glucose tolerance and
type 2 diabetes mellitus.
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on the nature of the variables (ie, the way in which b-
cell response and IS are expressed).6 In our study,
indices ranging from early insulin response (INSINDEX
and AUCINS/GLU-30) to whole insulin response
(AUCINS-180 and AUCINS/GLU-180) demonstrated
parameters for the b-cell response that fulﬁlled the crite-
ria for a rectangular hyperbolic relationship. The indices
INSINDEX
7,18,19 and AUCINS/GLU-30
7,22 are considered
to represent the ﬁrst phase insulin response in
humans,51 but a biphasic insulin release from the b-cells
has not been proven to occur in horses. The M-values
calculated from the EHC in our study were corrected
for NIMGU to avoid a confounding factor in the mea-
surement of IS. The contribution of NIMGU to total
M is relatively small in individuals with normal IS and
thus can be ignored.52 In IR individuals however the
relative importance of NIMGU increases considerably.
In our study, the estimated error of NIMGU to total
M ranged between 10 and 69% and thus represented a
heterogeneous error. A weakness with this correction is
that it is based on calculations with the assumption of a
linear relationship for NIMGU with blood glucose con-
centrations driven by a mass action eﬀect of glucose
similar for all horses. This glucose dose–response rela-
tionship has been proven for several species,26,53 and it
is constant as long as there is no increase in non-insu-
lin-dependent glucose uptake. This situation might
occur in human patients with type II diabetes54 or in
critically ill patients,55 but it is not applicable to the
horses in our study.
Several diﬀerent IS indices calculated from the OST
have been correlated to IS measured by the EHC in
humans.8,10,56–58 We studied 1 of these indices: ISICOMP,
8
previously used in horses.9,17 In addition, we formulated
3 new simpler OST indices (ISIPEAK, ISI60, and ISI90)
based on ISICOMP, but calculated them from only a sin-
gle blood sample during the dynamic OST. There was a
high correlation between all IS indices calculated from
the OST and IS measures from the EHC, where the more
simple indices (ISIPEAK, ISI60, and ISI90) showed as good
correlation as the more complex index (ie, ISICOMP). The
use of ISI60 or ISI90 enables IS to be estimated from the
OST with only a single blood sample.
The OST indices are mathematical variants of data
for the b-cell response, which by inversion have been
transformed to correlate linearly instead of hyperboli-
cally to IS measured by the EHC. Because the OST is a
quite nonspeciﬁc test for b-cell response,50 this bias will
be propagated to the estimates for IS, because it is cal-
culated from the same data. Due to the nonlinear
inverse relationship between the b-cell response and IS,
large changes in IS for horses with high IS will only
result in very small changes in insulin secretion. These
small variations in b-cell response will not be accurately
determined by the OST. The opposite situation with
more pronounced insulin secretions occurs for IR
horses, and OST-derived indices for IS will therefore
more accurately estimate IS under these conditions.
This is apparent in our data as shown in Figure 3,
where the relationship between IS indices and M/I
showed heteroscedasticity with higher variability for the
data in the range of high IS. The same pattern is evi-
dent when OST-derived indices of IS are compared to
IS quantiﬁed in humans.8
In conclusion, we have demonstrated that an
inverse relationship between b-cell response and IS
exists in horses. The hyperbolic paradigm between
b-cell response and IS also holds true for the horse.
Therefore, assessment of hyperinsulinemia as part of
the b-cell response should be interpreted in relation
to prevailing IS. The inverse relationship between
b-cell response and IS suggests that horses with ID
respond not only with postprandial hyperinsulinemia
after intake of nonstructural carbohydrates but are
also IR.
Footnotes
a Clinical Pathology Laboratory, University Animal Hospital,
Uppsala, Sweden
b Intranule, 2.0 9 105 mm. Vygon, Ecouen, France
c EMLA, AstraZenica AB, S€odert€alje, Sweden
d Nordic Sugar A/S, Copenhagen, Denmark
e Vacuette 9 mL, Greiner Bio-One GmbH, Kremsm€unster, Austria
f GraphPad Prism, version 6.0 for windows; GraphPad Software
Inc, San Diego, CA
g Glucose Fresenius Kabi 500 mg/mL, Fresenius Kabi AB, Upp-
sala, Sweden
h Humulin Regular, Eli Lilly Sweden AB, Solna, Sweden
i Colleague, Volumetric infusion pump, Baxter Healthcare SA,
Zurich, Switzerland
j Accu-Check Aviva, Roche Diagnostics Scandinavia AB,
Bromma, Sweden
k YSI 2300 Stat Plus Analyzer, YSI Incorporated, Yellow Spring,
Ohio
l Mercodia equine insulin ELISA, Mercodia AB, Uppsala, Sweden
m Mercodia animal insulin control (low, medium, high), Mercodia
AB, Uppsala, Sweden
n Mercodia insulin ELISA, Mercodia AB, Uppsala, Sweden
o Mercodia diabetes antigen control (low, high)/human, Mercodia
AB, Uppsala, Sweden
p SAS Institute Inc., Cary, NC
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